Effect of beraprost sodium, a stable prostaglandin I2 analogue, on platelet aggregation in diabetes mellitus

International Journal of Clinical Pharmacology Research

Volumn 16, Issue 4-5, 1996, Pages 99-102

  Kato, H ^a   Takashima, T ^a   Kishikawa, H ^a   Emura, S ^a   Ohmori, K ^a  

^a SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; BERAPROST; PROSTACYCLIN DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; THROMBOCYTE AGGREGATION; VASCULAR DISEASE;

ADULT; AGED; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; EPOPROSTENOL; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS;

EID: 0030429744     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Steiner G. Diabetes and atherosclerosis. An overview. Diabetes, 30 (Suppl. 2) 1, 1981.
2. Ross R., Glomset J.A. The pathogenesis of atherosclerosis (First of two parts). N. Engl. J. Med., 295, 369, 1976.
3. Shimokawa H., Vanhoutte P.M. Impaired endothelium-dependent relaxation to aggregating platelet and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis. Circ. Res., 64, 900, 1989.
4. Radomski M.W., Palmer R.M.J., Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J. Pharmac., 92, 181, 1987.
5. Kwaan H.C. et al. Increased platelet aggregation in diabetes mellitus. J. Lab. Clin. Med., 80, 236, 1972.
6. Umeda F. et al. Cyclic nucleotide phosphodiesterase and aggregation in platelets from diabetic rats. Metabolism, 31, 704, 1982.
7. Watanabe J. et al. Effect of vitamin E on platelet aggregation in diabetes mellitus. Tohoku J. Exp. Med., 143, 161, 1984.
8. Bensoussan D. et al. Platelet hyperaggregation and increased plasma level of von Willebrand factor in diabetics with retinopathy. Diabetologia, 11, 307, 1975.
9. Watanabe J. et al. Effect of prostaglandin synthetase inhibitors on platelet aggregation and thromboxane production in diabetes mellitus. Tohoku J. Exp. Med., 144, 143, 1984.
10. Moncada S. et al. An enzyme isolated from arteries trans-forms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation Nature, 263, 663, 1976.
11. Moncada S., Higgs E.A., Vane J.R. Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet, 1, 18, 1977
12. Bunting S et al. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins, 12, 897, 1976.
13. Moncada S., Vane J.R. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N. Engl. J. Med, 300, 1142, 1979.
14. Nishio S. et al. The in vitro and ex vivo antiplatelet effect of JRK-100, a stable prostacyclin analog, in several species. Jpn. J. Pharmacol., 47, 1, 1988
15. Paton P.C., Passa P. Platelets and diabetic vascular disease. Diabète Metab., 9, 306, 1983.